Back to Search
ELIAS JABBOUR, MD
MD
Pulmonary Disease Physician
NPI: 1598172082IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
LP03254(RI)MD17051(RI)
Critical Care Medicine (Internal Medicine) Physician
Internal Medicine — Critical Care Medicine
Code: 207RC0200X
MD17051(RI)
Pulmonary Disease PhysicianPrimary
Internal Medicine — Pulmonary Disease
Code: 207RP1001X
MD17051(RI)
Education
OTHER
Class of 2013
Research & Publications (20)
High prevalence of HBV genotype D in Syria and the clinical characteristics of hepatitis B e antigen-negative chronic hepatitis B.
PMID 19538827·Epidemiol Infect·2010
8-other
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.
PMID 19282457·Blood·2009
3-trial
Understanding the role of mutations in therapeutic decision making for chronic myeloid leukemia.
PMID 19621546·Semin Hematol·2009
8-other
Gemtuzumab Ozogamicin is a promising post-remission therapy for acute myeloid leukemia.
PMID 18571231·Leuk Res·2009
5-case
Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?
PMID 19181650·Mayo Clin Proc·2009
6-review
Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy.
PMID 19365094·Oncologist·2009
6-review
Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.
PMID 19506164·J Clin Oncol·2009
4-observational
Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia.
PMID 19235255·Cancer·2009
8-other
Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response.
PMID 19487383·J Clin Oncol·2009
4-observational
Treatment of myelofibrosis in younger patients: to transplant or not?
PMID 19202548·Am J Hematol·2009
8-other
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.
PMID 19567878·Blood·2009
8-other
Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia.
PMID 19109226·Blood·2009
8-other
Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.
PMID 19060245·Blood·2009
3-trial
Treatment selection after imatinib resistance in chronic myeloid leukemia.
PMID 19343297·Target Oncol·2009
6-review
Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.
PMID 18818391·Blood·2008
8-other
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.
PMID 18403620·Blood·2008
8-other
Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias.
PMID 18549348·Expert Opin Investig Drugs·2008
7-preclinical
Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors.
PMID 18615627·Cancer·2008
8-other
Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis.
PMID 18640568·Biol Blood Marrow Transplant·2008
8-other
Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules.
PMID 19254884·Clin Lymphoma Myeloma·2008
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 825 CHALKSTONE AVE
PROVIDENCE, RI 02908 - Phone
- (401) 456-2000
Quick Facts
- NPI
- 1598172082
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 4
- Locations
- 2
- Years in Practice
- 13
- Publications
- 20
Are you this provider?
Claim Your Profile